Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Karyopharm Therapeutics Inc. has received an average analyst rating of "Moderate Buy", with four analysts recommending buying the stock and one suggesting a hold.
• The company's 12-month price target is set at $34.00, though recent target adjustments have varied significantly, with some dropped to as low as $25.00.
• Karyopharm reported earnings of ($4.32) per share for the last quarter, falling short of the consensus estimate of ($3.80), despite revenue closely matching expectations.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $34.00.

Several brokerages have issued reports on KPTI. HC Wainwright lowered Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 16th. Robert W. Baird dropped their target price on Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Bridgeway Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics during the second quarter valued at approximately $163,000. Bank of America Corp DE raised its stake in shares of Karyopharm Therapeutics by 26.8% during the second quarter. Bank of America Corp DE now owns 168,534 shares of the company's stock valued at $726,000 after acquiring an additional 35,626 shares in the last quarter. Baird Financial Group Inc. bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $45,000. Silverback Asset Management LLC raised its stake in shares of Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company's stock valued at $302,000 after acquiring an additional 20,000 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $56,000. Hedge funds and other institutional investors own 66.44% of the company's stock.

Karyopharm Therapeutics Trading Down 2.9%

KPTI opened at $6.45 on Monday. The firm has a market cap of $55.92 million, a P/E ratio of -0.44 and a beta of 0.34. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $16.95. The stock has a 50-day moving average of $5.24 and a 200 day moving average of $5.20.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The business had revenue of $37.93 million during the quarter, compared to analyst estimates of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.